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Summary 
Purpose: The aim of this study was to examine the reporting quality of randomized 
controlled trials (RCTs) published during the last ten years concerning the use of Anti Tumor 
Necrosis (Anti-TN) Factors for Crohn’s Disease.  
 Methods: A thorough computerized search in the scientific network databases of 
Pubmed was conducted for Crohn’s Diseases and all the available Anti-TN Factors. The 
reporting quality was assessed using Consolidated Standards of Reporting Trails (CONSORT) 
statement checklist. Reporting was assessed in one pre-revision of CONSORT (2005-2010) 
and one post–revision (2010-2015) period. The effect of CONSORT statement in high- and 
low-ranked journals, according to their impact factor, has also been evaluated. 
 Results: 51 RCTs were indentified using eligible criteria from the title and the 
abstract. Only 15 of the 25 items of CONSORT statement were addressed in 75% or more of 
the studies. Methodological issues such as sample size, randomization, allocation, blinding 
and precision of estimated effect size were presented inadequately. Significant post-revision 
improvements were noted for the prior methodological items, while RCTs published in high-
ranked journals failed to show improvement in the quality of reporting. 
Conclusion: Overall, the reporting quality of RCTs in anti-TNF treatment of Crohn’s 
disease requires improvement. The revision of the CONSORT statement provides  significant 
details and information for robust and complete reporting of RCTs. This is of major 
importance since the optimal reporting of RCTs is an important prerequisite for the clinical 
decision –making. 
 
Keywords:  Anti-TNF, Crohn’s Disease, Randomized clinical trial, CONSORT statement, 
Adalimubad, Infiximab, Certolizumab pegol, Vedolizumab, Ustekinumab 
Abbreviations: Anti-TNF=Anti-Tumor Necrosis Factor, CD=Crohn’s Disease, CONSORT= 




Reliable evidence and robust conclusions are likely to be derived from strict design 
and accurate methodology (Juni et al 2001 and Moher et al 2010). Amongst the various 
study designs, the randomized controlled trial (RCT) is considered as the ‘gold standard’ for 
assessing the effectiveness and safety of medical interventions. On the contrary, RCTs are 
prone to inadequacies and bias and therefore, several studies indicate that the quality of 
many RCTs is substandard (Schulz et al 1994 and Moher et al 1995).  
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The urgency for accurateness and transparency led to the development of the 
Consolidated Standards of Reporting Trials (CONSORT) guidelines by the CONSORT group. 
The main CONSORT document consists of 25 items and sets standard on how and what 
should be included in a RCT report in order to improve the quality standards along with the 
validity of the results (Moher et al 2010). 
The CONSORT Statement is endorsed by over 580 prominent general medical 
journals, several specialty medical journals, leading editorial organizations and by over 50% 
of the core medical journals listed in the Abridged Index Medicus on PubMed. CONSORT is 
part of a broader effort, to improve the reporting of different types of health research and 
therefore to improve the quality of research used in decision-making in healthcare 
(CONSORT website assessed 2015).  In gastroenterology, reporting quality of RCTs has been 
assessed in a number of general and specialized journals (Xu et al 2015, Qi et al 2014, Wang 
et al 2011, Rupinski et al 2011 and Areia et al 2010) indicating the prospective for further 
improvement. Additional, Zhu et al (2015) assessed the quality of RCTs using the CONSORT 
statement regarding aspects of nutrition in patients with Crohn’s disease. However, there is 
a lack of studies comparatively evaluating recently published RCTs in efficacy and safety of 
Crohn’s disease treatment and remission (Ophélie et al 2014). 
Therefore, the primary objective of this study was to evaluate the reporting integrity 
of RCTs of Anti-Tumor Necrosis Factor (Anti-TNF) for Crohn’s disease efficacy, safety, 
treatment and remission.   
 
Materials and methods 
Data Sources, Search Strategies and Studies Selection 
A comprehensive computerized search of English language publications listed in the 
electronic databases of MEDLINE (source PUBMED) was conducted. The term “Crohn’s 
disease” was combined respectively with the terms “Adalimubad, Certolizumab pegol 
Infiximab, Vedolizumab and Ustekinumab” which are the common Anti-TN factors. A filter of 
“Randomized Controlled trial” was selected and a “10 years Publication date” was applied. 
Initially, the abstract was read and any trials that were clearly RCTs were included. Other 
articles that used terminology in the title or abstract such as ‘prospective’, ‘comparative’, 
‘efficacy’ or an indication was given that a comparison of treatment groups was assessed 
prospectively, were further investigated to examine whether randomization was 
implemented.  Studies that did not involve humans as well as studies, in which it was 
concluded that no true randomization was implemented, were excluded. Screening and 
selection of the studies were conducted by the author. 
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 Data Extraction and Reporting Assessment Tool 
 The information extracted from each of the article included the journal and the year 
of publication, the region of publication (Europe, Americas or other region), the ethical 
approval, the statistical significance of the main finding, the number of authors and whether 
the study was single centre or multicentre. The CONSORT checklist was used to evaluate the 
reporting completeness of RCTs. This checklist has 30 questions related to the CONSORT 
statements. The given score per statement ranged from 0 to 1, with 0 = no description and 1 
= adequate description. Alternatives responses (apart from yes or no) in addition with 
unclear responses to each question were coded as negative response (0). The scores of the 
25 statements were added, and a percentage score was calculated for each trial, whereas 
non-applicable items were not scored. A trial with adequate descriptions (score 1) for all 
items would receive a score of 25. All scores were converted to a percentage scale, and 
therefore, a score of 25 was equivalent to 100% in the percentage scale.  
 A revision of CONSORT checklist was conducted in 2010, which resulted in some 
evolutionary, but not revolutionary changes to the checklist. New additional items were 
added to improve the Consorts’ urge for completeness, clarity and transparency of reporting 
(Shluz et al 2010). 
 
Statistical analysis 
 Descriptive statistics were calculated for CONSORT scores and presented by trial 
characteristics. The numbers and proportions of the methodological items were reported by 
the publication years. The years were grouped into 2 periods: (1) trial reports published 
from 2005 until the CONSORT 2010 revision and (2) after the 2010 revision until July of 2015. 
The two time periods were compared to detect any improvement of reporting of CONSORT 
items, as well as to obtain an indication in improvement of validity and quality of RCTs. 
 The included studies were ranked according to the ISI (Institute for Scientific 
Information) impact factor (IF) list for 2015 and were divided into two groups in order to 
compare the adherence to the CONSORT statement of the articles in major IF medical 
journals (IF >10) with the remaining eligible papers (IF<10).The selection of IF<10 as the cut-
off point was arbitrary. 
 In this comparison, all CONSORT items were not concluded, but only those that were 
considered subjectively to be strongly related to trial validity. Although all items in the 
CONSORT checklist were considered important for the improvement of the quality of the 
RCTs’ reports, some were more subjective than others to assess potential biases. Emphasis 
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was placed on the reporting of the methodological items such as sample size, method of 
randomization and allocation concealment, performed statistical methods, description of 
baseline data, precision of estimated effect size, and reporting of Intention-to-treat (ITT) 
analysis.  
 Comparisons among periods as well as IF groups were made by using a chi-square 
test for trend. A P-value of 0.05 was considered statistically significant with a 95% 





 A total of 118 reports were screened after the Pubmed research and 7 were found 
to be duplicates (Figure 1).  After eligibility screening, 14 citations that could not be accessed 
plus another 3 citations that failed to provide a full text were excluded. Furthermore, 43 
citations that did not fulfill the inclusion criteria either by title or by abstract were excluded 
(i.e., RCTS for anti-TNF treatment of different diseases, RCTs in other subjects not relevant to 
Crohn’s disease, non randomized trials, narrative reviews or systematic reviews or meta-
analyses in Anti-TNF and Crohn’s disease and other studies in several types of inflammatory 
bowel disease). Consequently, a total of 51 reports remained for analysis, requiring 
complete full-text evaluation. A full list of the 51 reports that were retrieved as full-text and 
included in the final analysis is presented in table 4. The included RCTs referred to a wide 
selection of topics ranging from efficacy, remission, postoperative treatment, cost and 
recurrence. 
 
General trial characteristics 
 In Table 1 all the demographic and baseline characteristics of the 51 RCTs are 
presented. The journals contributing with the most RCTs were Gastroenterology (29.4%), 
followed by The America Journal of Gastroenterology (13.7%) and Clinical Gastroenterology 
and Hepatology (11.8%). The majority of RCTs were conducted under a global cooperation 
(45.1%) or under Europe and America contribution (19.6%). However, one RCT failed to 
provide information about ethical confirmation. 
 Most (90.2%) of the trials clearly demonstrated the application of a parallel-group 
design whilst one of them(2%) was clearly described as a cross over and the remaining (7.8 
%) were presented with confused information. Overall, 43.1 % of the trials investigated anti-
TNF as the primary intervention of interest regarding parameters as the efficacy and safety. 
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Fewer trials (33.3 %) investigate inferior aspects of Crohn’s disease such as hospitalization, 
quality of life and treatment cost and even fewer trials (21.6%) were focused on remission 
and maintenance of Crohn’s disease. One study was clearly focused only in recurrence of the 
disease (2.0 %). 
 The 84.3% of all reports clearly stated that trial’s data collected from several centers 
and 15.7% stated that the trial took place at a single center.  Most of the trails (74.5%) 
utilized double blind methods for medicine administration and analysis, 5.9 % applied single 
blind design and 19.6% were open labels trials. 70.6 % of all trials consisted of 2 study 
groups, while 29.4 % consisted of 3 or more groups. Twenty trials (39.2%) had sample size 
over 300, eighteen trials (35.3%) had sample size between 100 and 300 and thirteen trials 
(25.5%) had less than 100 patients as sample size. 
 According to the trails results and conclusions 80.4% of the trials reported 
statistically significant findings and moreover 56.9% of the trials were presented by Journals 
with Impact Factor greater to 10. Thirty-five trials (68.6%) were conducted by 7 to 11 
authors, fourteen trials (27.5%) were presented by over 12 authors and only two (3.9%) 
were signed by less than 6 authors. 
 
Main results 
 Table 2 shows information on the CONSORT compliances of the methodological 
items according to the publication periods of (1) 2005 to 2010 and (2) 2011 to July of 2015. 
Furthermore, of the 51 screened study reports, the 31 were published between 2005 -2010 
(pre-revision) and the 20 between 2011-2015 (post-revision). 
Only 15 items were reported by 75% or more of the studies in all of the time periods (see 
table 2). These include the following items: 
 Item No2: reporting of the objective/hypothesis of the study.  
 Item No3: description of the design and criteria.  
 Item No 4: reporting allocation and data collection. 
 Item No 5: reporting of interventions.  
 Item No 6: reporting of identification and definition of measures. 
 Item No 12: descriptions of statistical methods.  
 Item No 13: flow chart of protocol presentation.  
 Item No 14: reporting of end point and follow up.  
 Item No 15: reporting of baseline data in each group.  
 Item No 16: reporting of intention-to-treat principles.  
 Item No 18: reporting ancillary analysis.   
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 Item No 19: description of side/adverse effects. 
 Items No 20, 21, 22: descriptions of outcomes and reporting of summary results 
(interpretation, generalizability and overall evidence  
 In contrast, 10 items identified by data extraction were reported by only a small percentage 
of the trials in the two periods. These include the following item: 
 Item No 1: Justification of the trial, only in 47% of the studies the term “randomized 
was clearly demonstrated in the title”. On the other hand all studies used the term 
randomized in the abstract. 
 Item No 7: Sample calculation was only described by the 63 % of the studies.  
 Items No 8, 9, 10, 11: Only 47 - 63% of the reports provided the descriptions and the 
details of the randomization process, the allocation concealment, the personnel 
involved and the blinding procedure.  
 Item No 17: Complete reporting of the results with precision of estimated effect size 
(95% confidence intervals) was only demonstrated by 63% of the studies. 
 Items No 23, 24, 25: Other information such as registration number and funding was 
demonstrated adequately by 67-71% of the studies. 
Period Effect 
 CONSORT revision improved 23 of the 25 items. One item, justification of the trial, 
presented degeneration which was not statistical significant (P-value 0.61) (see table 2).  
 Significant improvements (p<0.05) over time were seen only for 5 out of 25 
CONSORT items, including:  
 Item No7: The description of the pre-study sample size calculation ( P-value=0.02, 
CI: 1.2 -15.6) 
 Item No8: The reporting of the randomization method ( P-value=0.02, CI: 1.2 -15.6) 
 Item No9: The description of the allocation concealment (P-value=0.04, CI: 1.01-
12.6) 
 Item No10: The details of personnel in sequence allocation ( P-value=0.02, CI: 1.2-
13.1)  
 Item No17: The reporting of results with precision to estimate effect size (P-
value=0.03, CI: 1.15- 15.6) 
 
Impact of CONSORT in High-Ranked Journals 
 
 Of the 51 study reports that were analyzed, 29 were published in high-ranked 
medical journals (IF>10.1) and 22 in lower ranked medical journals (IF<10). Table 3 shows 
the proportion of reporting of seven important CONSORT items for each of these two IF 
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groups and for the total analyzed papers. As previously noticed, these items provide critical 
information for the evaluation of the RCTs methodological quality. According to the results 
all journals have adhered adequate to the CONSORT statement.  Frequencies of reporting of 
all observed data items, have improved but not with statistical significance (p>0.05) in this 
group of studies. 
Discussion 
 In this study, the reporting quality of RCTs in the fields of Anti-TNF agents and 
Crohn’s Disease was assessed using CONSORT statement. The mean CONSORT scores ranged 
from 47% to 98% among the journals included in the study, a finding similar to the scores 
reported in medical journals (Turner et al 2012, Klouklos et al 2015). Although all quality 
score scales, have inherent limitations and caution that should be used when evaluating 
reporting quality, the overall score indicates that there is room for improvement.  Despite 
that surveys and studies similar to this one have been conducted previously; this study is the 
first which investigated the reporting of RCTs for Anti-TNF and Crohn’s Disease with 
particular reference to CONSORT, covering a period of the last 10 years. 
 Justification of the trial as a randomized trial was poor (47%) according to the titles 
of the studies; this finding was possible due to the limitations of the journals regarding the 
size of the title. On the contrary the abstracts of all studies provided all the necessary 
information about the justification of the trials.   
 Pre-study sample size calculation is an important part of designing a trial, as well as 
guards against underpowered trials that may result in research waste (Al-Shahi Salman et al 
2014). In the present study, 62% of the RCTs did not report sample size calculation at all or it 
was reported inadequately. Ziogas and Zintzaras (2009) reported that 37% of the 261 
medical trials published in PubMed from 1998 to 2008 did not report sample size 
calculation. It seems that problematic reporting of pre-study sample size calculations in RCTs 
is a common finding in literature (Lu et al 2015, Kloukos et al 2015). As pointed out by other 
studies, trials with inadequate power could result in a high false-negative error rate and are 
likely associated with publication bias (Schulz and Grimes 2015, Chan and Altman 2005). 
Post-CONSORT revision studies appear to assimilate the necessity of the sample size 
calculation, increasing the percentages of the studies with adequate sample size calculation 
to 84%. 
 Reporting the methods of randomization sequence generation and allocation 
concealment has shown that it is strongly associated with effect estimates (Savovic et al 
2012, Pildal et al 2007). For every RCT, the method of randomization is a key component to 
minimize any measured and unmeasured differences between the comparison groups. 
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Terms such as ‘patients were randomly assigned’ or ‘two groups were formed at random’ 
are considered inadequate. The current study showed that the generation of the 
unpredictable allocation sequence, allocation concealment and implementation was 
reported inadequately in 63%, 59% and 47%, of the cases respectively. However, the 
revision of CONSORT statement provided more details for the randomization and allocation 
improvement and therefore after the revision in the present study a statistical significant 
increase was reported in randomization and allocation procedures. A properly designed 
allocation concealment mechanism prevents selection bias and can always be successfully 
implemented (Savovic et al 2012). 
 Blinding is another important buffer against bias in RCTs and in some cases may not 
be feasible. Blinding is important to the validity of a trial, as it prevents performance and 
detection bias, and protects the sequence after allocation. Blinding is especially important 
for subjective outcomes (e.g. quality of life, discomfort, pain), as these are more prone to 
bias (Scluz and Grimes 2002,). Wood et al (2008) demonstrate that RCTs with unclear 
allocation concealment and non blinding procedures presented larger estimates of effects 
for subjective outcomes. The data of the present study suggest that there has been a 
significant improvement after the revision of CONSORT in reporting the quality parameters 
of allocation concealment. On the other hand, it should be clearly demonstrated as a topic 
of speculation that the current quality of reporting RCTs for parameters such as allocation 
enrolments and blinding participation are still below an acceptable level. Clark et al (2013) 
demonstrate similar results and speculations for the quality of key randomization and 
allocation concealment details. 
 Furthermore, the interpretation of the results demands unambiguous outcomes 
with statistical significance. Reporting of estimates and confidence intervals facilitates 
interpretation in relation to clinical importance. In the present study the CONSORT revision 
increase the thorough description of estimates and confidence interval but there is still vital 
space for improvement. Previous studies found inadequate results reporting in leading 
medical journals. Rios et al. (2008) found that Endocrinology trials also suffered from 
problematic reporting in this area of interest, with lack of description in 21% of the studied 
trials for the complete reporting of confidence interval.  
 Several limitations are ruling the present study. One limitation might be that the 
scoring of trials is always susceptible to some degree of subjectivity. Furthermore, the 
present study was only conducted using the most common medical database (PubMed) and 
therefore a main limitation is the lack of searching extension to Cochrane Collaboration 
database for more thorough and comparative exploration. 
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 It should be also underlined that incomplete reporting of trials does not necessarily 
infer to low quality of conducting or false methodology. Researchers might have designed 
and conducted a study ideally, but they might have omitted reporting accurately all stages 
and aspects of their trial due to several reasons such as space limitations (Soares et al 2004). 
This is also problematic because a biased but well-reported trial will receive full credit. Yet 
another potential limitation is the significant number of publication with no access to full 
text or the lack of a full text (14.4%) which is a significant proportion of studies whose 
inclusions might have changed the overall results. 
 
Conclusion 
 The effort of the current study was to assess the quality of RCTs focusing on the 
treatment of Crohn’s Disease with the use of Anti-TNFs. The results highlight the 
improvement of reporting of RCTs after the revision of the CONSORT checklist in 2010. 
Critical items for the quality of RCTs showed statistically significant improvement after 
revision, but some important methodological descriptions such as allocation concealment, 
blinding and estimates effect size, are still in the necessity of further enrichment. As far as 
the battle for treatment and remission of Crohn’s disease, the improvement of RCTs 
regarding refined medication such as Anti –TNF, will provide necessary and vital information 
for treatment decisions, risk, harms and future research. Especially nowadays in a period of 
new pharmaceutical and genetic discoveries and innovations, robust and crystal reports will 
facilitate to RCT interpretation, reduction of controversy conclusions and mainly to simplify 
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Database Medline Pubmed 
 
Adalimubad AND CD n=31 
Certolizumab AND CD n=19 
Infiximab AND CD n=59 
Vedolizumab AND CD n=6 




Screened for eligibility 
n=111 
 
Adalimubad AND CD n=30 
Certolizumab AND CD n=19 
Infiximab AND CD n=53 
Vedolizumab AND CD n=6 
Ustekinumab AND CD n=3 
 
Duplicates n=7 




-Not relevant topic n=28 
Adalimubad n= 1, Certolizumab n= 3, Infiximab n= 21, Vedolizumab n=3, 
Ustekinumab n=0 
-Not inclusion criteria by abstract n= 15 
Adalimubad n= 8, Certolizumab n= 2, Infiximab n= 5, Vedolizumab n=0, 
Ustekinumab n=0 
Excluded n =17 
-Unavailable Access n = 14 
Adalimubad n= 6, Certolizumab n= 1, Infiximab n= 7, Vedolizumab n=0, 
Ustekinumab n=0 
-Unavailable full text n =3 
Adalimubad n= 0, Certolizumab n= 0, Infiximab n= 3, Vedolizumab n=0, 
Ustekinumab n=0 
References retrieved as full text and included in final analysis: n=51 
 Adalimubad n= 15, Certolizumab n= 13, Infiximab n= 17, Vedolizumab n=3, Ustekinumab n=3 
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 Category N % 
Journal    
 Alimentary Pharmacology and Therapeutics 5 9.8 
 America Journal of Gastroenterology 7 13.7 
 Annals of internal Medicine 1 2.0 
 Clinical Gastroenterology and Hepatology 6 11.8 
 Digestive Disease and Science 1 2 
 Gastroenterology 15 29.4 
 Gut 5 9.8 
 International Journal of Colorectal Disease 1 2 
 Journal Of Crohn’s and Colitis 2 3.9 
 Lancet 1 2 
 The New England Journal of Medicine 5 9.8 
Trial location    
 Europe 9 17.6 
 Global 23 45.1 
 America/Europe 10 19.6 
 America 9 17.6 
Ethics committee approval    
 Yes 50 98.0 
 No 1 2.0 
Trial design    
 Parallel 46 90.2 
 Crossover 1 2.0 
 Other 4 7.8 
Intervention    
 Maintenance/Remission 11 21.6 
 Efficacy/Safety 22 43.1 
 Recurrence 1 2.0 
 Other 17 33.3 
Number of center    
 Multi center 43 84.3 
 Single center 8 15.7 
Trial design (blind/open)    
 Blind (double) 38 74.5 
 Blind (single) 3 5.9 
 Open label 10 19.6 
No of study groups    
 2 36 70.6 
 >3 15 29.4 
Sample size    
 <100 13 25.5 
 101-300 18 35.3 
 >301 20 39.2 
Statistical significance of 
main findings 
   
 Yes 41 80.4 
 No 10 19.6 
Journal’s impact factor    
 1-10.0 22 43.1 
 >10.1 29 56.9 
Number of authors    
 <6 2 3.9 
 7-11 35 68.6 
 >12 14 27.5 
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TABLE 2. Proportion of reporting of 25 data items in a total of 51 randomized controlled trials in 



















1. Justification for the trial 0.47 0.52 0.40 0.61 
0.24-2.3 
INTRODUCTION     
2. Clear statement of hypothesis or objectives 0.92 0.90 0.95 0.49 
0.21-23.0 
METHODS     
3. Description design, allocation ratio and modifications 0.94 0.94 0.95 0.77 
0.12-16.9 
4. Detailed description of setting/location of recruitment 
and data collection 
0.98 0.97 1.00 0.40 
0.91-1.0 
5. Details of intervention studied 0.94 0.94 0.95 0.77 
0.12-16.9 
6. Identification and definition of outcome measures 0.86 0.84 0.90 0.46 
0.33-10.9 
7. Description of pre-study sample size calculation 0.63 0.48 0.85 0.02 
1.2-15.6 
8. Description of the generation of unpredictable 
allocation sequence and details of any restriction used 
in randomization 
0.63 0.48 0.85 0.02 
1.1-15.6 
9. Description of allocation concealment 0.59 0.45 0.80 0.04 
1.01-12.6 
10. Details of personnel involved in sequence allocation, 
enrollment, and assignment 
0.47 0.32 0.70 0.02 
1.2-13.1 
11.  Details of blinding of participants, providers, assessors 
and analyst 
0.43 0.42 0.45 0.97 
0.32-3.0 
12. Description of statistical methods 0.98 0.97 1.00 0.40 
0.91-1.0 
RESULTS     
13. Flow chart describing patient numbers at different 
stages and clear description of protocol deviations 
0.75 0.74 0.75 0.67 
0.21-2.7 
14. Description of dates of recruitment and follow up 0.90 0.90 0.90 0.95 
0.16-6.9 
15. Description of  baseline characteristics 0.94 0.94 0.95 0.77 
0.12-16.9 
16. Reporting of intention-to-treat principle 0.75 0.74 0.75 0.82 
0.32-4.2 
17. Complete reporting of results with precision of 
estimated effect size 
0.63 0.52 0.80 0.03 
1.15-15.6 
18. Ancillary analysis 0.82 0.77 0.90 0.20 
0.54-15.6 
19. Description of side/adverse effects 0.86 0.81 0.95 0.12 
0.55-45.1 
DISCUSSSION     
20. Interpretation of the results 0.80 0.77 0.85 0.93 
0.26-4.4 
21. Generalizability 0.94 0.94 0.95 0.77 
0.12-16.9 
22. Overall evidence 0.88 0.87 0.90 0.69 
0.24-8.82 
OTHER INFORMATION     
23. Registration number and name of trial 0.67 0.65 0.70 0.55 
0.44-4.8 
24. Trail protocol availability 0.69 0.65 0.75 0.33 
0.53-6.5 
25. Sources of funding 0.71 0.61 0.85 0.05 
0.96-16.6 
* Percentage of articles reporting the CONSORT item. 
a
 P Values were obtained from chi-square tests for trend of associations between proportions for reporting an 
item and publication period across the two periods 
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TABLE 3. Proportion* of reporting of seven emphasized CONSORT data items in a total of 261 
randomized controlled trials in myeloid malignancies by impact factor group 




Low IF papers 
IF<10 
(n=22) 






1.Sample size 0.63 0.55 0.69 0.29 
0.59-5.85 
2.Method of randomization 0.63 0.55 0.69 0.29 
0.59-5.85 
3.Allocation concealment 0.59 0.45 0.69 0.09 
0.84-8.42 
4.Statistical method 0.94 0.91 0.97 0.38 
0.97-1.11 
5.Description of  baseline data 0.88 0.86 0.90 0.12 
0.98-1.26 
6.Intent-to-treat analysis 0.75 0.68 0.79 0.36 
0.50-6.37 
7.Precision of estimated effect size 0.63 0.59 0.66 0.63 
0.42-4.13 
IF = impact factor. 
*Percentage of articles reporting the CONSORT item. 
 
a 
Values were obtained from chi-square tests for trend of associations between proportions for reporting an item 
across the two groups of papers. 
 
Table 4. List of scored papers 
No Year Journal Issue 
(volume) 
First Author CONSORT 
% 
1 2005 Gastroenterology 128 Lichtenstein 60 
2 2005 Gastroenterology 129 Schreiber 88 
3 2006 Gastroenterology 130 Hanauer 72 
4 2006 Gastroenterology 130 Lemann 68 
5 2006 Gastrointestinal Endoscopy 63 (3) Rutgeerts 60 
6 2006 Alimentary Pharmacology and Therapy 23 Sands 52 
7 2007 Gastroenterology 132 Colombel 88 
8 2007 Gastroenterology 132 Hyams 80 
9 2007 The New England Journal of Medicine 357 Sandborn 80 
10 2007 Annals of Internal Medicine 146 Sandborn 100 
11 2007 Gut 56 Sandborn 76 
12 2007 The New England Journal of Medicine 357 Schreiber 96 
13 2008 Gastroenterology 134 Van Assche 68 
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